Edition:
United Kingdom

Trevena Inc (TRVN.OQ)

TRVN.OQ on NASDAQ Stock Exchange Global Select Market

1.68USD
4:31pm GMT
Change (% chg)

$-0.00 (-0.30%)
Prev Close
$1.68
Open
$1.70
Day's High
$1.71
Day's Low
$1.66
Volume
47,453
Avg. Vol
188,479
52-wk High
$5.16
52-wk Low
$1.35

Chart for

About

Trevena Inc. is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in... (more)

Overall

Beta: -0.51
Market Cap(Mil.): $151.63
Shares Outstanding(Mil.): 59.70
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Trevena Inc Says FDA Indicated To Co That PDUFA Date For Olinvo NDA Is Nov 2‍​

* TREVENA INC - ON JAN 5, FDA INDICATED TO THE CO THAT PDUFA REVIEW DATE FOR OLINVO NDA IS NOV 2‍​

05 Jan 2018

BRIEF-Trevena Announces FDA Acceptance For Review Of New Drug Application For OLINVO(Oliceridine) Injection

* TREVENA ANNOUNCES FDA ACCEPTANCE FOR REVIEW OF NEW DRUG APPLICATION FOR OLINVO (OLICERIDINE) INJECTION

02 Jan 2018

BRIEF-Trevena Inc says Q3 loss per share $0.27

* Trevena reports third quarter 2017 financial results and announces new positive clinical trial data

07 Nov 2017

BRIEF-Trevena announces submission of NDA to U.S. FDA for Olinvo

* Trevena announces submission of new drug application to U.S. FDA for Olinvo (oliceridine injection)

02 Nov 2017

BRIEF-‍trevena announces publication and presentations of olinvo clinical data​

* ‍Trevena announces publication and presentations of olinvo (oliceridine injection) clinical data​ Source text for Eikon: Further company coverage:

25 Oct 2017

BRIEF-Trevena announces restructuring to focus resources on commercial strategy

* Trevena announces restructuring to focus resources on commercial strategy

11 Oct 2017

Earnings vs. Estimates